Cesca therapeutics announces receipt of $2 million upfront distribution fee

Cesca therapeutics inc. and thermogenesis announced it has received the $2 million upfront distribution fee pursuant to its global distribution agreement, entered into as of august 30, 2019, for the x-series® product line. for details of the global distribution agreement, please refer to the company's 8-k filed with the u.s. securities and exchange commission on september 6, 2019. the x-series products are major components of the company's car-txpress™ platform, a semi-automated, closed cellular processing platform used for high efficiency cell purification and cell washing. the x-series products, when used in combination with the company's proprietary buoyancy activated cell sorting (bacs) technology, can be applied for both research and commercial manufacturing of a large variety of cell-based therapeutics, including chimeric antigen receptor-t (car-t) cells.
THMO Ratings Summary
THMO Quant Ranking